Table 2.
Follow‐up characteristics by tenofovir disoproxil fumarate intake and D:A:D chronic kidney disease risk strata
| Median (IQR) or N (%) | No TDF | TDF | ||||
|---|---|---|---|---|---|---|
|
Low‐risk (N = 2827) |
Medium‐risk (N = 481) |
High‐risk (N = 272) |
Low‐risk (N = 4743) |
Medium‐risk (N = 994) |
High‐risk (N = 485) |
|
| Duration of follow‐up (months) | 19.5 (13.0–27.5) | 18.6 (12.0–27.6) | 18.7 (12.0–27.7) | 28.8 (18.3–45.1) | 28.5 (16.8–44.8) | 27.2 (16.1–45.8) |
| Regimen discontinuation* | 850 (30%) | 183 (38%) | 122 (45%) | 4091 (86%) | 907 (91%) | 434 (90%) |
| Last eGFR (mL/min/1.73 m2) | 106.2 (91.5–118.3) | 89.5 (77.2–99.6) | 75.4 (65.3–90.3) | 107.5 (93.6–119.1) | 88.9 (75.8–100.5) | 79.3 (66.3–90.2) |
| Last eGFR < 60 mL/min/1.73 m2 | ≤ 5 † | 9 (5%) | 22 (18%) | 39 (1%) | 49 (5%) | 67 (15%) |
eGFR, estimated glomerular filtration rate; IQR, interquartile range; TDF, tenofovir disoproxil fumarate.
*
Regimen discontinuation defined as discontinuation of any antiretroviral agent or regimen switch.
†
Cell count ≤ 5 deemed insufficient for reporting.